Tumor microenvironment changes tumor cell sensitivity to action of energy metabolism modifiers


  • O.N. Pyaskovskaya R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • D.L. Kolesnik R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • I.V. Prokhorova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • A.P. Burlaka R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O.I. Gorbach R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • G.I. Solyanik R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology




metformin, sodium dichloroacetate, tumor growth and metastasis


Summary. Background: Taking into account differences in the bioenergetics between malignant and normal cells a search of antitumor drugs among the modifiers of tumor metabolism has a reasonable excuse. Earlier it was found that the cytotoxic/cytostatic action of sodium dichloroacetate (DCA) against Lewis lung carcinoma (LLC) cells in vitro was enhanced in the case of its combination with metformin (MTF). Aim: To study the antitumor action of DCA in combination with MTF against LLC in vivo. Materials and Methods: LLC/R9, a low metastatic variant of LLC cells, was used. LLC/R9 bearing mice were treated with MTF (at a total dose 0.15 g/kg b.w.) alone or in combination with DCA (at a total dose of 0.75 g/kg b.w.). LLC/R9 growth kinetics and the primary tumor growth and metastasis indices on the 23rd day after tumor cell inoculation were evaluated by routine procedures. The state of the electron transport chain of mitochondria in tumor cells was studied using electron paramagnetic resonance. The content of lactate and glucose in blood plasma from mice was measured by enzymatic methods using biochemical analyzer. The number of tumor-associated macrophages (TAMs) and their distribution by M1/M2 phenotype were estimated by flow cytometry using antibodies against CD68 and CD206. Results: In LLC/R9-bearing mice treated with DCA in combination with MTF, tumor growth and metastasis indices, as well as circulating glucose and lactate levels were not significantly different from those in the control group. The level of nitrosylation of non-heme and heme proteins and the content of iron-sulfur centers in the mitochondria of tumor cells in LLC/R9-bearing mice administered with DCA in combination with MTF did not also differ from the corresponding indices in control. Instead, in tumors treated with MTF alone and in combination with DCA the total CD68+ TAMs count was almost 27% (p < 0.05) and 43% lower (p < 0.05) correspondingly than that in control, but this decrease was not accompanied by redistribution of CD68+/CD206+ and CD68+/D206- subsets. Conclusion: DCA in combination with MTF, at least in doses applied, did not affect LLC/R9 growth and metastasis in vivo. The complete absence of an antitumor effect of DCA in combination with MTF was simultaneously associated with the absence of significant changes in the functional state of electron transport chain of mitochondria in tumor cells, circulating glucose and lactate levels, and the decrease of the TAMs amount in tumors. It suggests that the antitumor activity of DCA and MTF could be determined by both their local effects within a tumor and their multiple systemic impacts.


Zhang W, Zhang S-L, Hu X, Tam KY. Targeting tumor metabolism for cancer treatment: Is pyruvate dehydrogenase kinases (PDKs) a viable anticancer target? Int J Biol Sci 2015; 11: 1390–400.

Luengo A, Gui DY, Heiden MGV. Targeting metabolism for cancer therapy. Cell Chem Biol 2017; 24: 1161–80.

Stacpoole PW. Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis in cancer. J Natl Cancer Inst 2017; 109. https://doi.org/10.1093/jnci/djx071.

Stacpoole PW, Barnes CL, Hurbanis MD et al. Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 1997; 77: 535–41.

Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99: 989–94.

Duan Y, Zhao X, Ren W, et al. Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation. Onco Targets Ther 2013; 6: 189–98.

Tataranni T, Agriesti F, Pacelli C, et al. Dichloroacetate affects mitochondrial function and stemness-associated properties in pancreatic cancer cell lines. Cells 2019; 8: 478.

Feuerecker B, Seidl C, Pirsig S et al. DCA promotes progression of neuroblastoma tumors in nude mice. Am J Cancer Res 2015; 5: 812–20.

Jia HY, Wang HN, Xia FY et al. Dichloroacetate induces protective autophagy in esophageal squamous carcinoma cells. Oncol Lett 2017; 14: 2765–70.

Lu X, Zhou D, Hou B, et al. Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer. Cancer Manag Res 2018; 10: 1231–41.

Florio R, De Lellis L, Veschi S, et al. Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells. Scie Rep 2018; 8: 13610.

Pyaskovskaya ON, Kolesnik DL, Fedorchuk AG, et al. 2-deoxy-D-glucose enchances dichloroacetate antitumor action against Lewis lung carcinoma. Exp Oncol 2016; 38: 176–80.

Fedorchuk AG, Pyaskovskaya ON, Gorbik GV, et al. Effectiveness of sodium dichloroacetate against glioma С6 depends on administration schedule and dosage. Exp Oncol 2016; 38: 80–3.

Kolesnik DL, Pyaskovskaya ON, Yurchenko OV, Solyanik GI. Metformin enhances antitumor action of sodium dichloroacetate against glioma C6. Exp Oncol 2019; 41: 123–9.

Prokhorova IV, Pyaskovskaya ON, Kolesnik DL, Solyanik GI. Influence of metformin, sodium dichloroacetate and their combination on the hematological and biochemical blood parameters of rats with glioma C6. Exp Oncol 2018, 40: 205–10.

Kolesnik DL, Pyaskovskaya ON, Gorbach O, Solyanik GI. Metformin enhances cytotoxic action of dichloroacetate against Lewis lung carcinoma cells in vitro. Exp Oncol 2020, 42: 35–9.

Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348: 607–14.

Fontaine E. Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences. Front Endocrinol (Lausanne) 2018; 9: 753. https://doi.org/10.3389/fendo.2018.00753.

Pulatova MK, Kuropteva ZV, Rihireva GT. Electron paramagnetic resonance in molecular radiobiology. Energoatomizdat, 1989: 228 pp.

Falini B, Flenghi L, Pileri S, et al. PG-M1: A new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am J Pathol 1993; 142: 1359–72.

Tan HY, Wang N, Man K, et al. Autophagy-induced RelB/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin. Cell Death Dis 2015; 6: e1942.

Serezhenkov VA, Kuznetsov IS, Romantsova T, Vanin AF. Antidiabetes drug metformin is a donor of nitric oxide: EPR measurement of efficiency. Biofizika 2012; 56: 1125–33.

Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889–96.

Xu L, Zhu Y, Chen L, et al. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol 2014; 21: 3142–50.

Ohashi T, Akazawa T, Aoki M, et al. Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int J Cancer 2013; 133: 1107–18.

Wang JC, Sun X, Ma Q, et al. Metformin’s antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization. J Cell Mol Med 2018; https://doi.org/10.1111/jcmm.13655.

Poh AR, Ernst M. Targeting macrophages in cancer: from bench to bedside. Front Oncol 2018; 8: 49. https://doi.org/10.3389/fonc.2018.00049.




How to Cite

Pyaskovskaya, O., Kolesnik, D., Prokhorova, I., Burlaka, A., Gorbach, O., & Solyanik, G. (2023). Tumor microenvironment changes tumor cell sensitivity to action of energy metabolism modifiers. Experimental Oncology, 42(3), 192–196. https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-3.14981



Original contributions

Most read articles by the same author(s)

1 2 > >>